# A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies

> **NCT05861947** · PHASE1 · TERMINATED · sponsor: **Aurigene Discovery Technologies Limited** · enrollment: 21 (actual)

## Conditions studied

- Relapse
- Advanced Malignant Neoplasm
- Non Small Cell Lung Cancer
- Gastric Cancer
- Urothelial Carcinoma
- Kidney Cancer
- Colon Cancer
- Esophagus Cancer

## Interventions

- **DRUG:** AUR106

## Key facts

- **NCT ID:** NCT05861947
- **Lead sponsor:** Aurigene Discovery Technologies Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-26
- **Primary completion:** 2026-02-10
- **Final completion:** 2026-02-10
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Patient recruitment problems
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05861947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05861947, "A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05861947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*